Uni-Bio Science Group Limited (HKG:0690)

Market Cap	525.47M +10.0%
Revenue (ttm)	586.21M +6.0%
Net Income	93.33M +12.7%
EPS	0.02 +15.7%
Shares Out	5.97B
PE Ratio	5.64
Forward PE	n/a
Dividend	0.00 (3.56%)
Ex-Dividend Date	May 28, 2026

Volume	280,000
Open	0.0850
Previous Close	0.0880
Day's Range	0.0850 - 0.0870
52-Week Range	0.0820 - 0.1680
Beta	-0.04
Analysts	n/a
Price Target	16.10 (+18,620.93%)
Earnings Date	Mar 27, 2026

About Uni-Bio Science Group

Uni-Bio Science Group Limited, an investment holding company, researches and develops, manufactures, and sells biological and chemical pharmaceutical products to treat human diseases in Hong Kong, and People’s Republic of China. It operates through Chemical Pharmaceutical Products, Biological Pharmaceutical Products, and Pipeline Products segments. The company provides BOGUTAI, a disposable injection pen for the treatment of osteoporosis; GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndro...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 543
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 0690

Financial Performance

In 2025, Uni-Bio Science Group's revenue was 586.21 million, an increase of 6.01% compared to the previous year's 552.98 million. Earnings were 93.33 million, an increase of 12.75%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 18, 2026

Data Sources Report a data error